Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 200Neoplasms 116Breast Neoplasms 112Colorectal Neoplasms 97Ovarian Neoplasms 78Prostatic Neoplasms 75Neoplasm Metastasis 74Lung Neoplasms 66Multiple Myeloma 64Squamous Cell Carcinoma of Head and Neck 49Pancreatic Neoplasms 48Endometrial Neoplasms 48Recurrence 46Stomach Neoplasms 39Carcinoma, Renal Cell 39Small Cell Lung Carcinoma 38Melanoma 38Leukemia, Lymphocytic, Chronic, B-Cell 38Leukemia, Myeloid, Acute 34Lymphoma, Non-Hodgkin 30Urinary Bladder Neoplasms 29Parkinson Disease 4, Autosomal Dominant Lewy Body 29Triple Negative Breast Neoplasms 28Head and Neck Neoplasms 26Carcinoma, Hepatocellular 26Lymphoma, Large B-Cell, Diffuse 25Lymphoma, Follicular 25Esophageal Neoplasms 24Advanced Solid Tumors 24Lymphoma 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Neuromyelitis Optica × 30 days × Clear all
NCT06680037 2026-05-18

A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders

TG Therapeutics, Inc.

Phase 1 Recruiting
100 enrolled

Multiple Sclerosis, Myasthenia Gravis, Neuromyelitis Optica, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡